SEC 13F Intelligence

Baker Bros. Advisors LP / MDGL

Baker Bros. Advisors LP’s Madrigal Pharmaceuticals Inc Position

Does Baker Bros. Advisors LP own Madrigal Pharmaceuticals Inc (MDGL)? Yes — 2.14M shares worth $1.1B (+6.44% of its 13F portfolio) as of Q1 2026.

Position Value
$1.1B
Q1 2026
Shares
2.14M
% of Portfolio
+6.44%
Quarters Held
30
currently held

Position History MDGL

Reported value by quarter
Q4 ’18: $132MQ4 ’18Q1 ’19: $146MQ2 ’19: $123MQ3 ’19: $101MQ4 ’19: $107MQ4 ’19Q1 ’20: $100MQ2 ’20: $170MQ3 ’20: $178MQ4 ’20: $167MQ4 ’20Q1 ’21: $175MQ2 ’21: $146MQ3 ’21: $120MQ4 ’21: $127MQ4 ’21Q1 ’22: $147MQ2 ’22: $107MQ3 ’22: $97MQ4 ’22: $448MQ4 ’22Q1 ’23: $374MQ2 ’23: $357MQ3 ’23: $226MQ4 ’23: $456MQ4 ’23Q1 ’24: $526MQ2 ’24: $553MQ3 ’24: $419MQ4 ’24: $609MQ4 ’24Q1 ’25: $654MQ2 ’25: $598MQ3 ’25: $982MQ4 ’25: $1.2BQ4 ’25Q1 ’26: $1.1Bfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20262.14M$1.1B+6.44%
Q4 20252.14M$1.2B+7.30%
Q3 20252.14M$982M+7.10%
Q2 20251.98M$598M+5.80%
Q1 20251.97M$654M+7.24%
Q4 20241.97M$609M+6.51%
Q3 20241.97M$419M+4.34%
Q2 20241.97M$553M+7.07%
Q1 20241.97M$526M+6.60%
Q4 20231.97M$456M+5.19%
Q3 20231.55M$226M+1.30%
Q2 20231.55M$357M+2.07%
Q1 20231.55M$374M+2.04%
Q4 20221.55M$448M+2.69%
Q3 20221.50M$97M+0.64%
Q2 20221.50M$107M+0.61%
Q1 20221.50M$147M+0.85%
Q4 20211.50M$127M+0.62%
Q3 20211.50M$120M+0.53%
Q2 20211.50M$146M+0.64%
Q1 20211.50M$175M+0.76%
Q4 20201.50M$167M+0.63%
Q3 20201.50M$178M+0.71%
Q2 20201.50M$170M+0.75%
Q1 20201.50M$100M+0.62%
Q4 20191.17M$107M+0.57%
Q3 20191.17M$101M+0.69%
Q2 20191.17M$123M+0.83%
Q1 20191.17M$146M+0.94%
Q4 20181.17M$132M+1.08%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Baker Bros. Advisors LP’s full portfolio or all institutional holders of MDGL.